| Size | Price | |
|---|---|---|
| Other Sizes |
| ADME/Pharmacokinetics |
Metabolism / Metabolites
There is a group of genetic disorders, known as the porphyrias that are characterized by errors in metabolic pathways of heme synthesis |
|---|---|
| Toxicity/Toxicokinetics |
Protein Binding
This means that the oxygen binding curve for fetal hemoglobin is left-shifted (i.e., a higher percentage of hemoglobin has oxygen bound to it at lower oxygen tension), in comparison to that of adult hemoglobin |
| References | |
| Additional Infomation |
The respiratory protein of the red blood cells. It consists primarily of globin and heme.
See also: Hemoglobins (annotation moved to). Drug Indication Investigated for use/treatment in blood (blood forming organ disorders, unspecified) and hemorrhage. Mechanism of Action A heme group is made up of iron (Fe) ion (charged atom) located in a heterocyclic ring, which is also called a porphyrin ring. The site of oxygen binding, the iron ion, binds with the nitrogens located in the center of the porphyrin ring. The iron ion binds with high affinity to the globular protein through the imidazole ring of the F8 residue on histidine which is found below the porphyrin ring. A sixth position can bind reversibly to oxygen, completing the formation of the octahedral group. One oxygen atom binds Fe and the other is found to protrude at an angle. When oxygen is not bound to Fe, a water molecule (weakly bound) fills the site, producing a distorted shape, often described as an octahedron. |
| Molecular Weight |
0
|
|---|---|
| Exact Mass |
226.074
|
| CAS # |
9008-02-0
|
| PubChem CID |
13285535
|
| Appearance |
Brown to reddish brown solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
400.9±45.0 °C at 760 mmHg
|
| Flash Point |
196.3±28.7 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.609
|
| LogP |
2.95
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
17
|
| Complexity |
353
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
INGWEZCOABYORO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H10N2O2/c1-8-4-5-9-11(16)7-10(15-13(9)14-8)12-3-2-6-17-12/h2-7H,1H3,(H,14,15,16)
|
| Chemical Name |
2-(furan-2-yl)-7-methyl-1H-1,8-naphthyridin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
An evaluation of pressure ulcer using fingerstall-type tissue oximetry
CTID: UMIN000032921
PhaseNot applicable Status: Complete: follow-up complete
Date: 2018-07-01
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
